- Home
- VSTE vs TRAW Comparison
VSTE vs TRAW Comparison
Compare VSTE & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTE
- TRAW
- Stock Information
- Founded
- VSTE 2009
- TRAW 1998
- Country
- VSTE Australia
- TRAW United States
- Employees
- VSTE N/A
- TRAW N/A
- Industry
- VSTE
- TRAW
- Sector
- VSTE
- TRAW
- Exchange
- VSTE Nasdaq
- TRAW NYSE
- Market Cap
- VSTE 10.6M
- TRAW 10.1M
- IPO Year
- VSTE N/A
- TRAW 2013
- Fundamental
- Price
- VSTE $0.32
- TRAW $2.32
- Analyst Decision
- VSTE
- TRAW
- Analyst Count
- VSTE 0
- TRAW 0
- Target Price
- VSTE N/A
- TRAW N/A
- AVG Volume (30 Days)
- VSTE 11.0M
- TRAW 48.8K
- Earning Date
- VSTE 01-01-0001
- TRAW 03-31-2025
- Dividend Yield
- VSTE N/A
- TRAW N/A
- EPS Growth
- VSTE N/A
- TRAW N/A
- EPS
- VSTE N/A
- TRAW N/A
- Revenue
- VSTE $6,193,000.00
- TRAW $226,000.00
- Revenue This Year
- VSTE N/A
- TRAW $3.81
- Revenue Next Year
- VSTE N/A
- TRAW N/A
- P/E Ratio
- VSTE N/A
- TRAW N/A
- Revenue Growth
- VSTE 443.25
- TRAW N/A
- 52 Week Low
- VSTE $0.28
- TRAW $2.01
- 52 Week High
- VSTE $9.10
- TRAW $24.75
- Technical
- Relative Strength Index (RSI)
- VSTE 30.50
- TRAW 31.50
- Support Level
- VSTE $0.28
- TRAW $2.52
- Resistance Level
- VSTE $0.37
- TRAW $2.69
- Average True Range (ATR)
- VSTE 0.04
- TRAW 0.27
- MACD
- VSTE 0.01
- TRAW 0.08
- Stochastic Oscillator
- VSTE 15.00
- TRAW 25.20
About VSTE Vast Renewables Limited
Vast Renewables Ltd is a clean, renewable energy company specializing in the design and manufacturing of concentrated solar thermal power (CSP) systems to generate carbon-free, utility-scale electricity, industrial heat, and green fuels. The Company's differentiated modular CSP system, utilizing proprietary sodium loop heat transfer technology, provides customers with a solution to the enduring challenge of intermittent renewable energy through 24/7 dispatchable power and heat.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.